Compare CTNT & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTNT | INDP |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 5.2M |
| IPO Year | 2023 | 2021 |
| Metric | CTNT | INDP |
|---|---|---|
| Price | $2.69 | $1.77 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 168.3M | 51.9K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.74 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,288,536.00 | N/A |
| Revenue This Year | $42.49 | N/A |
| Revenue Next Year | $22.22 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 182.69 | N/A |
| 52 Week Low | $0.02 | $0.27 |
| 52 Week High | $4.21 | $13.24 |
| Indicator | CTNT | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 64.10 | 34.21 |
| Support Level | $1.48 | $1.71 |
| Resistance Level | $4.21 | $2.08 |
| Average True Range (ATR) | 0.34 | 0.30 |
| MACD | 0.19 | -0.18 |
| Stochastic Oscillator | 64.30 | 1.13 |
Cheetah Net Supply Chain Service Inc is a provider of logistics and warehousing services, historically in connection with the sale of parallel-import vehicles sourced in the U.S. to be sold in the PRC market, and more recently for the transportation of other goods between the U.S. and the PRC. Parallel-import vehicles in the PRC refer to automobiles purchased directly from overseas markets and imported for sale outside of the brand manufacturer's official distribution networks. The company operates as single report segment. The company operates in the USA and overseas.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.